Suchergebnisse - "Voorhees, Peter"

PubPharm (14)

1

A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Bhutani, M. | Foureau, D. | Robinson, M. | +14

2

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma : Analysis of vascular thrombotic events in the GRIFFIN study

enthalten in: British journal of haematology | 2022

von Sborov, D. | Baljevic, M. | Reeves, B. | +18

3

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

enthalten in: American journal of hematology | 2021

von Voorhees, P. | Suman, V. | Tuchman, S. | +9

4

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma : long-term survival follow-up from the Phase II study O-12-M1

enthalten in: British journal of haematology | 2021

von Bringhen, S. | Voorhees, P. | Plesner, T. | +8

5

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma : analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

enthalten in: Blood cancer journal | 2020

von Richardson, P. | Lee, H. | Abdallah, A. | +13

6

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma : the GRIFFIN trial

enthalten in: Blood | 2020

von Voorhees, P. | Kaufman, J. | Laubach, J. | +26

CommentIn: Blood. 2020 Aug 20;136(8):917-918. - PMID 32818244

7

Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Ailawadhi, S. | Sexton, R. | Lentzsch, S. | +11

8

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma : a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

enthalten in: Leukemia | 2020

von Landgren, C. | Chari, A. | Cohen, Y. | +18

9

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2) : a two-arm, randomised, open-label, phase 2 study

enthalten in: The Lancet. Oncology | 2020

von Lonial, S. | Lee, H. | Badros, A. | +35

10

Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma

enthalten in: Leukemia research | 2019

von Hari, P. | Paba-Prada, C. | Voorhees, P. | +6